COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 2431: Articles 24301-24310  | Next

Host metabolic reprogramming in response to SARS-Cov-2 infection
Moolamalla, S. T. R., Chauhan, R., Priyakumar, U. D., Vinod, P. K.
10.1101/2020.08.02.232645 — Posted: 2020-08-05 Discussion: Onsite | Offsite
Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale
Esra, R. T., Jamesion, L., Fox, M. P., Letswalo, D., Ngcobo, N., Mngadi, S., Estill, J. G., Meyer-Rath, G., Keiser, O.
10.1101/2020.07.30.20164939 — Posted: 2020-08-05
Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay
Machado, R. R. G., Glaser, T., Araujo, D. B., Petiz, L. L., Oliveira, D. B. L., Durigon, G. S., Leal, A. L., Pinho, J. R. R., Ferreira, L. C. S., Ulrich, H., Durigon, E. L. R., Guzzo, C. R.
10.1101/2020.08.04.235549 — Posted: 2020-08-04
Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis
Bull, R. A., Adikari, T., Hammond, J. M., Stevanovski, I., Ferguson, J. M., Beukers, A. G., Naing, Z., Yeang, M., Verich, A., Gamaarachichi, H., Kim, K. W., Luciani, F., Stelzer-Braid, S., Eden, J.-S., Rawlinson, W. D., van Hal, S. J., Deveson, I. W.
10.1101/2020.08.04.236893 — Posted: 2020-08-04
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., Ho, D. D.
10.1101/2020.08.03.235291 — Posted: 2020-08-04
Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection
Seo, S. H., Jang, Y.
10.1101/2020.08.04.235689 — Posted: 2020-08-04
SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic
Ghanchi, N. K., Masood, K. I., Nasir, A., Khan, W., Abidi, S. H., Shahid, S., Mahmood, S. F., Kanji, A. R., Razzak, S. A., Ansar, Z., Islam, N., Dharejo, M. B., Hasan, Z., Hasan, R.
10.1101/2020.08.04.234153 — Posted: 2020-08-04 Discussion: Onsite
Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.
Carozzi, F. M., Cusi, M. G., Pistello, M., Galli, L., Bartoloni, A., Anichini, G., Azzari, C., Emdin, M., Gandolfo, C., Maggi, F., Mantengoli, E., Moriondo, M., Moscato, G., Paganini, I., Passino, C., Profili, F., Voller, F., Zappa, M., Quattrone, F., Rossolini, G. M., Francesconi, P., SARS-CoV-2 Serosurvey Tuscan Working Group
10.1101/2020.07.30.20149567 — Posted: 2020-08-04
Overcoming Reporting Delays Is Critical to Timely Epidemic Monitoring: The Case of COVID-19 in New York City
Harris, J. E.
10.1101/2020.08.02.20159418 — Posted: 2020-08-04
Pathogenetic Perspective of Missense Mutations of ORF3a Protein of SARS-CoV2
Hassan, S. S., Attrish, D., Ghosh, S., Pal Choudhury, P., Roy, B.
10.1101/2020.08.04.236653 — Posted: 2020-08-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).